Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report
Open Access
- 6 February 2020
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 8 (3) , 624-629
Abstract
Oncologic immunotherapy is attracting attention as an effective strategy for cancer treatment. Currently, there are two kinds of inhibitors: Anti-PD-1 antibodies and anti-PD-L1 antibodies. These inhibitors have shown significant implications in improving the outcomes of certain cancer types in recent years. However, along with its effectiveness, adverse events cannot be ignored. As an anti-PD-1 antibody, camrelizumab (SHR-1210) has some side effects in tumor immunotherapy. The most common adverse event is reactive capillary hemangioma. While it is widely reported to occur in the skin, gingival reactive capillary hemangioma is rarely reported. A 54-year-old man complained of gingival overgrowth on the anterior aspect of the maxilla and mandible for more than 6 mo. He had been placed on SHR-1210 for lung cancer for 7 mo. A gingival mass extending from canine to canine was noted on the lingual surfaces of the mandible. Gingival enlargement was noted in the front teeth. A clinical diagnosis of gingival reactive capillary hemangioma and chronic periodontitis was made. The treatment involved a complex local treatment (repeated local applications of an antibiotic paste, scaling and root planning, and surgery). The excised tissue was sent for histopathological examination, which confirmed the diagnosis of capillary hemangioma. After the operation, most of the gingival enlargement was reduced. At the 2-mo follow-up, it was noted that the gingival overgrowth was immediately reduced after the replacement of the anti-PD-1 agent with an anti-PD-L1 agent. As the prescription for SHR-1210 has increased considerably in recent years, the occurrence of its possible side effects, including gingival reactive capillary hemangioma, has increased. It is recommended that regular oral examinations be performed before and during the treatment of tumors with SHR-1210.Keywords
This publication has 19 references indexed in Scilit:
- A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin LymphomaClinical Cancer Research, 2019
- Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapyPharmacology & Therapeutics, 2019
- Reactive capillary hemangiomas induced by camrelizumab (SHR-1210), an anti-PD-1 agentActa Oncologica, 2019
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion StudyClinical Cancer Research, 2019
- Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210Cancer Biology & Medicine, 2019
- The association between oral hygiene and periodontitis: a systematic review and meta-analysisInternational Dental Journal, 2017
- Periodontal diseasesNature Reviews Disease Primers, 2017
- Antagonists of PD-1 and PD-L1 in Cancer TreatmentSeminars in Oncology, 2015
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- Gingival hyperplasia associated with nifedipine therapyOral Surgery, Oral Medicine, Oral Pathology, 1984